Lbp Am Sa Has $31.32 Million Stock Position in Abbott Laboratories (NYSE:ABT)

Lbp Am Sa reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 13.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 276,934 shares of the healthcare product maker’s stock after selling 42,272 shares during the quarter. Lbp Am Sa’s holdings in Abbott Laboratories were worth $31,324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ABT. Impax Asset Management Group plc lifted its position in shares of Abbott Laboratories by 0.5% during the 3rd quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock worth $63,573,000 after buying an additional 2,754 shares during the last quarter. United Bank raised its position in Abbott Laboratories by 1.8% in the third quarter. United Bank now owns 27,284 shares of the healthcare product maker’s stock valued at $3,111,000 after purchasing an additional 488 shares during the last quarter. Versor Investments LP bought a new position in Abbott Laboratories in the third quarter valued at about $651,000. Pinnacle Financial Partners Inc raised its position in Abbott Laboratories by 6.4% in the third quarter. Pinnacle Financial Partners Inc now owns 51,094 shares of the healthcare product maker’s stock valued at $5,825,000 after purchasing an additional 3,090 shares during the last quarter. Finally, Cable Hill Partners LLC raised its position in Abbott Laboratories by 7.8% in the third quarter. Cable Hill Partners LLC now owns 9,698 shares of the healthcare product maker’s stock valued at $1,106,000 after purchasing an additional 705 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the transaction, the executive vice president now owns 74,381 shares of the company’s stock, valued at $10,277,222.77. The trade was a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last 90 days. 0.47% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 0.4 %

NYSE ABT opened at $129.71 on Friday. The business has a 50 day simple moving average of $126.90 and a 200 day simple moving average of $119.29. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The stock has a market capitalization of $224.97 billion, a P/E ratio of 16.96, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.82%. Abbott Laboratories’s dividend payout ratio is presently 30.85%.

Wall Street Analyst Weigh In

Several equities analysts have commented on ABT shares. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $135.00 target price on shares of Abbott Laboratories in a research report on Tuesday, January 21st. StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Barclays restated an “overweight” rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Finally, Evercore ISI raised their price objective on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $137.94.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.